A Study of the Safety of IMOVAX Polio™ in China

Inclusion Criteria : * Subject is more than 2 months (60-89 days) old when receiving the first dose of polio vaccine. * Subject's parents/legal representative showed willingness to complete the 3 primary doses fully using IMOVAX Polio™ according to the schedule: one injection at 2, 3, 4 months old, respectively. * Informed consent form obtained from the subject's parent/legal representative. * Subject plan to live in the selected study sites for at least three months after inclusion. Exclusion Criteria : * Subject with a history of serious illness (e.g., hypersensitivity, seizure, convulsion, encephalopathy diseases) * Known or suspected impairment of immunologic function * Acute medical illness with or without fever within the last 72 hours * Subject plan to leave the study sites for at least three months after inclusion * Administration of immune globulin or other blood products within the last three months * Participation in another clinical trial at the same time * Contraindication to vaccination according to IMOVAX Polio™ leaflet.